More talk about doing “something” about drug prices sends drug stocks down
It's good to know that in this sometimes confusing and volatile market some things remain constant. A high-profile figure says something about the need to lower drug prices and drug stocks tumble. Whether the "something" is likely to result in action or not. Today it...
Adding Nektar call options to my Volatility Portfolio–again
Again. I'm adding the January 17, 2020 Call Options with a strike at $35 on Nektar Theraeutics (NKTR) to my Volatility Portfolio on JubakAM.com and JugglingWithKnives.com. (Ticker on these options is NKTR200117C00035000.) The underlying shares closed at $33.70, up...
Incyte adds to Jakafi label with new FDA approval
Jubak Picks and Volatility Portfolio member Incyte (INCY) closed up 1.55% today to $81.75 on news that the U.S. Food and Drug Administration had approved the company's Jakafi for treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the...
JNJ earnings a tale of two companies
On April 16, Johnson & Johnson beat Wall Street estimates by 6 cents a share. Revenue for the first quarter of 2019 climbed 0.1% to $20.02 billion, above the $19.55 billion projected by Wall Street.But the results really reflected the very different fortunes of the company’s stagnant consumer business and its strongly growing drug business.
Dividend Portfolio member Merck continues Keytruda momentum
Merck's cancer drug Keytruda continues to build global momentum. Today Merck (MRK) announced that China has approved Keytruda for first-line treatment of metastatic nonsquamous non-small cell lung cancer in combination with chemotherapy. The stock, which is a member...
Government action on drug prices seems far, far away
The format was familiar: Seven CEOs sit in front of a Senate Committee probing their industry's business practices. But whereas a Congressional hearing a decade ago marked a key moment in what was a costly public reckoning for the tobacco industry, today's hearing...
Adding Ionis Pharmacueticals to my Special Report: 10 Best Buy Stocks for After the Bear–and to my Volatility Portfolio
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Syneos, another small cap stock to watch (or to buy if you think the bear is over)
Back on November 27, I launched a "Special Report: My 10 small company stock picks for the January Effect." What with tremendous volatility in the market, the beginning of a bear market for some sectors, and the failure of the January Effect to arrive on schedule in...
Buying Pfizer for my Dividend Portfolio
I'm going to take advantage of the selling in the market in general and in the drug sector in particular--on news of the asbestos liability at Johnson & Johnson and fears of the death of Obamacare (AKA the Affordable Care Act)--to buy Pfizer (PFE) in my Dividend...
Sangamo makes regulatory progress; adding it to Special Report “Picks for a January Effect Rally”
As an investor in Sangamo (SGMO) the very slow and cautious pace of regulatory action at the U.S. Food & Drug Administration is frustrating. The FDA has only slowly allowed the company to expand the number of patients enrolled in the the safety trials for its new...
